Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
52.87
+0.05 (0.09%)
At close: May 1, 2026, 4:00 PM EDT
52.60
-0.27 (-0.52%)
After-hours: May 1, 2026, 7:39 PM EDT
Soleno Therapeutics Employees
Soleno Therapeutics had 182 employees as of December 31, 2025. The number of employees increased by 90 or 97.83% compared to the previous year.
Employees
182
Change
90
Growth
97.83%
Revenue / Employee
$1,046,181
Profits / Employee
$112,500
Market Cap
2.73B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 182 | 90 | 97.83% |
| Sep 30, 2025 | 152 | 60 | 65.22% |
| Jun 30, 2025 | 133 | - | - |
| Mar 31, 2025 | 115 | 82 | 248.48% |
| Dec 31, 2024 | 92 | 59 | 178.79% |
| Dec 31, 2023 | 33 | 8 | 32.00% |
| Dec 31, 2022 | 25 | 5 | 25.00% |
| Dec 31, 2021 | 20 | 3 | 17.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Denali Therapeutics | 503 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Vera Therapeutics | 249 |
| Celldex Therapeutics | 198 |
| Immunome | 177 |
| Disc Medicine | 155 |
SLNO News
- 2 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Soleno Therapeutics, Inc. Lawsuit - SLNO - GlobeNewsWire
- 18 days ago - Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers - GlobeNewsWire
- 18 days ago - Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 24 days ago - SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - GlobeNewsWire
- 26 days ago - Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - Reuters
- 27 days ago - Neurocrine to Buy Soleno for $2.9 Billion - WSJ
- 27 days ago - Neurocrine to buy Soleno Therapeutics for $2.9 billion - Reuters
- 27 days ago - Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PRNewsWire